生物活性 | |||
---|---|---|---|
描述 | Erdosteine effectively inhibits lipopolysaccharide (LPS)-induced NF-κB activation, demonstrating its anti-inflammatory capabilities[1].[2]. Additionally, Erdosteine is recognized for its muco-modulatory, antibacterial, anti-inflammatory, and antioxidant effects[3]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03368053 | Infection, Human Immunodeficie... 展开 >>ncy Virus 收起 << | Phase 1 | Completed | - | Belgium ... 展开 >> GSK Investigational Site Gent, Belgium, 9000 收起 << |
NCT02109354 | HIV Infection | Phase 1 | Unknown | April 2016 | South Africa ... 展开 >> Emavundleni Desmond Tutu HIV Centre CRS Cape Town, Western Cape, South Africa, 7750 Aurum Institute for Health Research Klerksdorp, South Africa, 2570 Perinatal HIV Research Unit Soweto, South Africa, 2013 收起 << |
NCT00223080 | - | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
4.01mL 0.80mL 0.40mL |
20.06mL 4.01mL 2.01mL |
40.11mL 8.02mL 4.01mL |
参考文献 |
---|
[3]Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment |